Can a Two-Drug combo curb Binge-Eating and help weight loss?
NCT ID NCT03946111
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This study tested whether a combination of naltrexone and bupropion can reduce binge-eating episodes and promote weight loss in people with binge-eating disorder and obesity. Participants took either the drug combo or a placebo for 12 weeks. The trial was very small, with only 3 people enrolled, so results are preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Department of Psychiatry
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naltrexone and bupropion combination
What this could lead to
If it works, this could offer a medication option to reduce binge-eating episodes and support weight loss in people with obesity.
What could go wrong
This is a very small, early-phase study with only 3 participants, so results may not apply broadly. The drug combo may cause side effects like nausea or insomnia.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.